ERBB2 and inflammatory breast carcinoma: Here too, LCN2 expression was higher in ER‐negative IBC patients compared to ER‐positive (P = 0.0009; Fig. 1D) and in more aggressive subtypes, ERBB2‐positive and TNBC, compared to hormone receptor (HR)‐positive/ERBB2‐negative subtype (Fig. 1E).